What Is SERMORELIN+GHRP-6 BLEND 2MG/2MG?
Sermorelin is a synthetic analog of growth hormone secretagogue. It binds to the receptors in the anterior pituitary gland and stimulates the release of growth hormone. Research indicates that sermorelin has been shown to build muscle mass. Furthermore, it improves cardiovascular function, increases sleep quality, and manages symptoms of dementia [1, 2, 3].
Similarly, GHRP-6 ( growth hormone-releasing peptide-6) is also a man-made analog of ghrelin receptors that stimulates growth hormone release. It has also been shown to exert similar effects, including improved heart function and enhanced muscle mass [4, 5]. Research on animal model indicates that it can boost memory, increase immunity and stimulates appetite [6, 7, 8].
As both peptides stimulate growth hormone release, combining them might give a synergistic effect. Further, the blends might enhance the peptide’s secondary effects and offer additional benefits, such as preventing osteoporosis and enhanced neuroprotection. At Pinnacle Peptides, the sermorelin + GHRP-6 blend for sale is exclusively available for research and experimentation.
References
- Bagno, L.L., et al., Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. J Am Heart Assoc, 2015. 4(4).
- Kanashiro-Takeuchi, R.M., et al., New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget, 2015. 6(12): p. 9728-39.
- Benedict, C., C.D. Chapman, and H.B. Schiöth, Growth Hormone–Releasing Hormone Improves Cognitive Function in Older Adults: Sleep On It. JAMA Neurology, 2013. 70(4): p. 529-530.
- Berlanga, J., et al., Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clinical Science, 2007. 112(4): p. 241-250.
- Xu, X.-B., et al., GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. American Journal of Physiology-Heart and Circulatory Physiology, 2005. 289(4): p. H1643-H1651.
- Madhavadas, S., B.M. Kutty, and S. Subramanian, Amyloid beta lowering and cognition enhancing effects of ghrelin receptor analog [D-Lys (3)] GHRP-6 in rat model of obesity. Indian J Biochem Biophys, 2014. 51(4): p. 257-62.
- Ghersi, M.S., et al., Ghrelin increases memory consolidation through hippocampal mechanisms dependent on glutamate release and NR2B-subunits of the NMDA receptor. Psychopharmacology, 2015. 232(10): p. 1843-1857.
- Subirós, N., et al., Assessment of dose–effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurological Research, 2016. 38(3): p. 187-195.
SERMORELIN+GHRP-6 BLEND 2MG/2MG
| Molecular Formula | Molecular Weight | CAS Number | SKU |
|---|---|---|---|
| Dual-peptide blend | N/A | N/A | SERM-GHRP6-BLEND |
The Sermorelin + GHRP-6 Research Blend co-delivers 2mg of Sermorelin (GHRH 1-29 NH2) and 2mg of GHRP-6 in a single lyophilised preparation, representing one of the most widely referenced dual-pathway GHRH/GHSR receptor activation formats in published research literature.
Employed in in vitro research examining cooperative GHRHR and GHSR-1a co-stimulation in dual-receptor cell line models and cAMP accumulation assays. The co-lyophilised format ensures reproducible fixed-ratio compound delivery across experimental replicates.
Both components synthesised to 99%+ purity and independently verified by HPLC and Mass Spectrometry before precision blending. USA-manufactured by Pinnacle Peptides. Reconstitute with bacteriostatic water. Store at -20C.
WARNING: For research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.

